INMB Stock Analysis: Buy, Sell, or Hold?
INMB - INmune Bio Inc. Common stock
$1.23
0.10 (8.85%)
▲
5d:
+0.82%
30d:
-12.14%
90d:
-23.13%
BUY
MODERATE Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: Mar 30, 2026
0d
Smart Money Accumulation
INMB is down 4.3% this week, but smart money is accumulating calls. Top strike: $1.5 2026-06-18 with 196 OI. Call ratio: 100% View Scanner →
Strength: 7.1/10
Get Alerted When INMB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: INMB shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: INMB shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: INMB is currently trading at $1.23, which is considered slightly low relative to its 30-day fair value range of $1.19 to $1.35.
Technical Outlook: Technically, INMB is in a strong downtrend. Immediate support is located at $1.09, while resistance sits at $1.29. The stock is showing strong short-term momentum, up 8.8% recently.
Market Sentiment: INMB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $7.00 (+469.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, INMB is in a strong downtrend. Immediate support is located at $1.09, while resistance sits at $1.29. The stock is showing strong short-term momentum, up 8.8% recently.
Market Sentiment: INMB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $7.00 (+469.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$1.19 -
$1.35
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+8.8%)
- BULLISH: Trading 469.1% below Wall St target ($7.00)
Fair Price Analysis
30-Day Fair Range
$1.19 -
$1.35
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$0.16
(13.2%)
Support & Resistance Levels
Support Level
$1.09
Resistance Level
$1.29
Current Trend
Strong Downtrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.58
Wall Street Target
$7.00
(+469.1%)
Revenue Growth (YoY)
257.1%
Share & Embed Analysis
Last updated: April 02, 2026 6:05 AM ET
Data refreshes hourly during market hours. Next update: 7:05 AM
Data refreshes hourly during market hours. Next update: 7:05 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INMB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 63 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 65 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 62 BUY |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$547 | 52 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$119 | 59 HOLD |
